Advanced Search

 

Study ID Status Title Patient Level Data
204888 Not yet recruiting HO-15-15503 - Qualitative Interviews and Survey: Understanding how the attributes of Relvar/Breo convey patient benefits – Asthma and COPD
204889 Recruiting Efficacy, safety and immunogenicity study of GSK Biologicals’ candi-date malaria vaccine (SB257049) evaluating schedules with or with-out fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age
204890 Withdrawn Skin Acceptability Assessment of the cosmetic product SM Translucent, in subjects with all Skin Types Under Normal Usage Conditions.
204891 Withdrawn Skin Acceptability Assessment of the cosmetic product SM Light Beige, in subjects with all Skin Types Under Normal Usage Conditions.
204892 Withdrawn Skin Acceptability Assessment of the cosmetic product SB Translucent, in subjects with all Skin Types Under Normal Usage Conditions.
204894 Not yet recruiting A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants
204896 Withdrawn Skin Acceptability Assessment of the cosmetic product SM Medium Beige, in subjects with all Skin Types Under Normal Usage Conditions.
204897 Withdrawn Skin Acceptability Assessment of the cosmetic product SB Peach Beige, in subjects with all Skin Types Under Normal Usage Conditions.
204898 Withdrawn Skin Acceptability Assessment of the cosmetic product SB Light Beige, in subjects with all Skin Types Under Normal Usage Conditions
204899 Withdrawn Skin Acceptability Assessment of the cosmetic product SB-Medium Beige, in subjects with all Skin Types Under Normal Usage Conditions.
204900 Completed PGx7642: Meta-analysis of data from FCGR PGx evaluations of ofatumumab CLL studies OMB110911, OMB114242, OMB115991 and OMB110913
204901 Completed PGx7644: Meta-analysis of data from SLE patients treated with Benlysta in studies BEL112341, BEL110752/BLISS-52/C1056, and BEL110751/BLISS-76/C1057
204905 Withdrawn Skin Acceptability Assessment of the cosmetic product SM Light Beige, in subjects with sensitive skin Under Normal Usage Conditions.
204906 Withdrawn Skin Acceptability Assessment of the cosmetic product SM Medium Beige, in subjects with sensitive skin Under Normal Usage Conditions
204907 Withdrawn Skin Acceptability Assessment of the cosmetic product SM Translucent, in subjects with sensitive skin Under Normal Usage Conditions
204908 Withdrawn Skin Acceptability Assessment of the cosmetic product SM Peach Beige, in subjects with sensitive skin Under Normal Usage conditions
204913 Active, not recruiting A long-term follow-up study of the investigational GSK Biologicals’ GSK3277511A vaccine in adults
204917 Withdrawn Comedogenic and acnegenic potential evaluation with ophthalmologic evaluation of the cosmetic product SB Translucent - in-use study.
204918 Withdrawn Comedogenic and acnegenic potential evaluation with ophthalmologic evaluation of the cosmetic product SB Light Beige - in-use study.
204919 Withdrawn Comedogenic and acnegenic potential evaluation with ophthalmologic evaluation of the cosmetic product SB Peach Beige - in-use study.
204920 Withdrawn Comedogenic and acnegenic potential evaluation with ophthalmologic evaluation of the cosmetic product SB Medium Beige - in-use study.
204921 Withdrawn Comedogenic and acnegenic potential evaluation with ophthalmologic evaluation of the cosmetic product SM Light Beige - in-use study.
204922 Withdrawn Comedogenic and acnegenic potential evaluation with ophthalmologic evaluation of the cosmetic product SM Medium Beige - in-use study.
204923 Withdrawn Comedogenic and acnegenic potential evaluation with ophthalmologic evaluation of the cosmetic product SM Translucent - in-use study.
204924 Withdrawn Comedogenic and acnegenic potential evaluation with ophthalmologic evaluation of the cosmetic product SM Peach Beige - in-use study.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.